Technical Analysis for SPPI - Spectrum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 11.58 -8.60% -1.09
SPPI closed down 8.6 percent on Thursday, December 13, 2018, on approximately normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical SPPI trend table...

Date Alert Name Type % Chg
Dec 13 New 52 Week Closing Low Bearish 0.00%
Dec 13 New 52 Week Low Weakness 0.00%
Dec 13 Stochastic Reached Oversold Weakness 0.00%
Dec 13 Below Lower BB Weakness 0.00%
Dec 13 Lower Bollinger Band Touch Weakness 0.00%
Dec 13 Oversold Stochastic Weakness 0.00%
Dec 12 20 DMA Resistance Bearish -8.60%
Dec 12 Outside Day Range Expansion -8.60%
Dec 12 Oversold Stochastic Weakness -8.60%
Dec 11 MACD Bearish Signal Line Cross Bearish -9.53%

Older signals for SPPI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Is SPPI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.29
52 Week Low 11.38
Average Volume 1,171,682
200-Day Moving Average 18.1946
50-Day Moving Average 13.3448
20-Day Moving Average 13.0515
10-Day Moving Average 13.085
Average True Range 0.7875
ADX 19.74
+DI 18.9145
-DI 30.5842
Chandelier Exit (Long, 3 ATRs ) 12.2875
Chandelier Exit (Short, 3 ATRs ) 13.7425
Upper Bollinger Band 14.3925
Lower Bollinger Band 11.7105
Percent B (%b) -0.05
BandWidth 20.549362
MACD Line -0.3159
MACD Signal Line -0.2198
MACD Histogram -0.0961
Fundamentals Value
Market Cap 912.33 Million
Num Shares 78.8 Million
EPS -1.00
Price-to-Earnings (P/E) Ratio -11.58
Price-to-Sales 11.56
Price-to-Book 7.68
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.67
Resistance 3 (R3) 13.83 13.30 13.32
Resistance 2 (R2) 13.30 12.77 13.22 13.20
Resistance 1 (R1) 12.44 12.44 12.18 12.28 13.09
Pivot Point 11.91 11.91 11.78 11.83 11.91
Support 1 (S1) 11.05 11.38 10.79 10.89 10.07
Support 2 (S2) 10.52 11.05 10.44 9.96
Support 3 (S3) 9.66 10.52 9.84
Support 4 (S4) 9.50